Share on LinkedInShare on LinkedIn

ARTICLE · 16 MAY 2024

Ophthalmic, Parenteral, & Otic Drug Development: Does FDA's Draft Guidance Provide A Vehicle To Avoid Patent Problems?

In April 2022, FDA released a proposed draft guidance (FDA Dock. No. 2022-D-0108) involving pH adjusters in drug development relating to ophthalmic, parenteral, or otic drug products.

United StatesIntellectual Property

In April 2022, FDA released a proposed draft guidance (FDA Dock. No. 2022-D-0108) involving pH adjusters in drug development relating to ophthalmic, parenteral, or otic drug products. The Draft Guidance suggests that FDA may entertain proposed ANDA formulations that differ in the pH adjuster in the ANDA formulation as compared to the Reference Listed Drug (RLD). This may be important for ANDA developers because typically the proposed ANDA drug product will match the RLD formulation composition so that the ANDA drug product is Q1/Q2 to the RLD. But savvy RLD holders will also have patents that match the RLD formulation, usually with spot on patent claims (e.g., a so-called "picture claim") that cause potential infringement issues for the ANDA developers. And of course there's nothing wrong with a patent holder obtaining broad and narrower formulation patent claims. It's part of a good strategy as part of its return on investment. But for ANDA developers the FDA and IP

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from